Have participated in this study previously, or any other study using exenatide or GLP-1 analogs. 
Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening. 
Have characteristics contraindicating metformin or sulfonylurea use. 
Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening. 
Have used drugs for weight loss within 1 month of screening.       
    

NCT00324363_exc_T1
Drug
GLP-1 analogs
NCT00324363_exc_T2
Observation
this study
NCT00324363_exc_T4
Observation
any other study
NCT00324363_exc_T3
Drug
exenatide
NCT00324363_exc_T6
Scope
this study previously, or any other study
NCT00324363_exc_T7
Observation
interventional study
NCT00324363_exc_T8
Observation
medical study
NCT00324363_exc_T9
Observation
surgical study
NCT00324363_exc_T10
Observation
pharmaceutical study
NCT00324363_exc_T11
Temporal
within 30 days of screening
NCT00324363_exc_T12
Scope
interventional, medical, surgical, or pharmaceutical study
NCT00324363_exc_T14
Drug
metformin
NCT00324363_exc_T15
Drug
sulfonylurea
NCT00324363_exc_T16
Condition
characteristics contraindicating
NCT00324363_exc_T17
Scope
metformin or sulfonylurea
NCT00324363_exc_T18
Drug
exogenous insulin
NCT00324363_exc_T19
Multiplier
for more than 1 week
NCT00324363_exc_T20
Temporal
within the 3 months prior to screening
NCT00324363_exc_T22
Drug
drugs for weight loss
NCT00324363_exc_T23
Temporal
within 1 month of screening
NCT00324363_exc_T5
Scope
exenatide or GLP-1 analogs
NCT00324363_exc_T13
Reference_point
screening
NCT00324363_exc_T21
Reference_point
screening